Monte Rosa Therapeutics Inc Stock

$4.16

1.22% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

US61225M1027

Symbol

GLUE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Monte Rosa Therapeutics Inc Stock price

$4.16

-17.02 80.36% 5Y

Nasdaq, Closing price Tue, May 20 2025

+0.05 1.22%

ISIN

US61225M1027

Symbol

GLUE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$255.88m
Enterprise Value	$-28.33m
P/E (TTM) P/E ratio	61.90
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	-0.18
P/S ratio (TTM) P/S ratio	1.60
P/B ratio (TTM) P/B ratio	0.93
Revenue growth (TTM) Revenue growth	14,889.38%
Revenue (TTM) Revenue	$159.49m
EBIT (operating result TTM) EBIT	$-2.13m
Free Cash Flow (TTM) Free Cash Flow	$30.48m
Cash position	$326.07m
EPS (TTM) EPS	$0.07
P/E forward	negative
P/S forward	2.60
EV/Sales forward	negative
Short interest	16.98%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Monte Rosa Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

8x Buy

89%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

Buy

89%

Hold

11%

Analyst Estimates with Stock Price Targets

Financial data from Monte Rosa Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	159 159	14,946% 14,946% 100%
- Direct Costs	8.27 8.27	19% 19% 5%
Gross Profit	151 151	2,663% 2,663% 95%
- Selling and Administrative Expenses	27 27	0% 0% 17%
- Research and Development Expense	118 118	13% 13% 74%
EBITDA	6.14 6.14	104% 104% 4%
- Depreciation and Amortization	8.27 8.27	19% 19% 5%
EBIT (Operating Income) EBIT	-2.13 -2.13	99% 99% -1%
Net Profit	6.15 6.15	105% 105% 4%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Monte Rosa Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

13 days ago

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant prostate cancer patients resistant to AR therapy; additional results expected in H2 2025 MRT...

Neutral

GlobeNewsWire

●

23 days ago

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 MGD delayed resistance to CDK4/6 inhibition in vitro and displayed superior selectivity versus clinical-stage CDK2 inhibitors BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Monte Ro...

Neutral

Seeking Alpha

●

2 months ago

Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic Finance Markus Warmuth - Chief Executive Officer Filip Janku - Chief Medical Officer Sharon Townson - Chief Scientific Officer Phil Nickson - Chief Business and Legal Officer Conference Call Partic...

More Monte Rosa Therapeutics Inc News

Company Profile

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Head office	United States
CEO	Markus Warmuth
Employees	134
Founded	2019
Website	www.monterosatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now